AA
CMPX icon

ACT Advisors’s Compass Therapeutics CMPX Stock Holding History

ACT Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1K Buy
+20,613
New +$60.9K 0.02% 73
2025
Q4 		– Sell
-10,376
Closed -$36.3K – 68
2025
Q3 		$36.3K Hold
10,376
– – 0.01% 66
2025
Q2 		$27K Sell
10,376
-385
-4% -$794 0.01% 57
2025
Q1 		$20.4K Buy
10,761
+233
+2% +$620 0.01% 54
2024
Q4 		$15.3K Buy
+10,528
New +$17.5K 0.01% 53

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACT Advisors's CMPX Position: Q2 2026 in Review

ACT Advisors opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 20,613 shares worth $45.1K. The stake represents 0.02% of the portfolio and ranks #73 among its holdings. This is a return to the name: ACT Advisors previously reported a position in CMPX as recently as Q3 2025.

ACT Advisors first reported a position in CMPX in Q4 2024 and has held it in 5 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • ACT Advisors held 20,613 shares of Compass Therapeutics worth $45.1K as of Q2 2026.
  • Compass Therapeutics was a new ACT Advisors position in Q2 2026.
  • Compass Therapeutics made up 0.02% of ACT Advisors's portfolio in Q2 2026, its #73 holding.
  • ACT Advisors first reported a position in Compass Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on ACT Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.